Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.260

+1.6%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Savant who wrote (3452)

12/17/2014 3:37:13 AM

From: Savant

of 3576

Geron announces publication of preclinical data demonstrating activity of imetelstat on leukemic stem cells from acute myelogenous leukemia

Co announced the publication of preclinical data demonstrating activity of the company's telomerase inhibitor drug, imetelstat, on leukemic stem cells from acute myelogenous leukemia (AML). In addition, the preclinical study showed the role of telomerase in AML disease initiation and progression. These data provide preclinical proof-of-concept to support clinical development of imetelstat in AML.

In the study, mice were transplanted with AML grafts from normal and telomerase deficient donor mice. Mice that received telomerase deficient grafts were shown to have reduced LSC functions and experienced cell cycle arrest and programmed cell death. This resulted in prolonged survival of telomerase deficient AML mice as compared to normal AML mice, providing proof-of-principle of the role of telomerase in maintaining LSCs.
To test telomerase as a pharmacological target for AML treatment, xenograft mice were engrafted with primary AML patient samples and treated with or without imetelstat. Imetelstat treatment resulted in inhibition of disease progression and prolonged survival in these mice. In addition, imetelstat was shown to inhibit disease relapse after doxorubicin chemotherapy in the AML xenografts. These data suggest that imetelstat has the potential for disease-modifying activity in AML by targeting LSCs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next